[go: up one dir, main page]

Feng et al., 2013 - Google Patents

A small molecule bidentate-binding dual inhibitor probe of the LRRK2 and JNK kinases

Feng et al., 2013

View PDF
Document ID
1523683600176051413
Author
Feng Y
Chambers J
Iqbal S
Koenig M
Park H
Cherry L
Hernandez P
Figuera-Losada M
LoGrasso P
Publication year
Publication venue
ACS chemical biology

External Links

Snippet

Both JNK and LRRK2 are associated with Parkinson's disease (PD). Here we report a reasonably selective and potent kinase inhibitor (compound 6) that bound to both JNK and LRRK2 (a dual inhibitor). A bidentate-binding strategy that simultaneously utilized the ATP …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Similar Documents

Publication Publication Date Title
Yamazoe et al. Heterobifunctional molecules induce dephosphorylation of kinases–a proof of concept study
Urick et al. Dual screening of BPTF and Brd4 using protein-observed fluorine NMR uncovers new bromodomain probe molecules
Koch et al. Inhibitors of c-Jun N-terminal kinases: an update
Millies et al. Proline-based allosteric inhibitors of Zika and Dengue virus NS2B/NS3 proteases
Yin et al. Terphenyl-based Bak BH3 α-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL
Lu et al. SHAFTS: a hybrid approach for 3D molecular similarity calculation. 2. Prospective case study in the discovery of diverse p90 ribosomal S6 protein kinase 2 inhibitors to suppress cell migration
Hartshorn et al. Fragment-based lead discovery using X-ray crystallography
Stebbins et al. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site
Louis et al. Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors
De et al. Design, synthesis, and structure− activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase
Yu et al. Rational design of small-molecule inhibitors for β-catenin/T-cell factor protein–protein interactions by bioisostere replacement
Novaroli et al. Impact of species-dependent differences on screening, design, and development of MAO B inhibitors
Wells et al. SGC-AAK1-1: a chemical probe targeting AAK1 and BMP2K
Statsuk et al. Tuning a three-component reaction for trapping kinase substrate complexes
Tomašić et al. Dual inhibitor of MurD and MurE ligases from Escherichia coli and Staphylococcus aureus
Baumli et al. The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508
Stebbins et al. Design and characterization of a potent and selective dual ATP-and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor
Allimuthu et al. 2-Chloropropionamide as a low-reactivity electrophile for irreversible small-molecule probe identification
Feng et al. A small molecule bidentate-binding dual inhibitor probe of the LRRK2 and JNK kinases
Tiefenbrunn et al. Small molecule regulation of protein conformation by binding in the flap of HIV protease
Good et al. Implications of promiscuous Pim-1 kinase fragment inhibitor hydrophobic interactions for fragment-based drug design
Stains et al. A p38α-selective chemosensor for use in unfractionated cell lysates
Brandvold et al. Exquisitely specific bisubstrate inhibitors of c-Src kinase
Liu et al. Development of alkyne-containing pyrazolopyrimidines to overcome drug resistance of Bcr-Abl kinase
Xiao et al. Dynamics of protein kinases: insights from nuclear magnetic resonance